^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    1d
    A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    8d
    NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=327, Recruiting, UNICANCER | Active, not recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    8d
    KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B) (clinicaltrials.gov)
    P2, N=102, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • MK-0482 • MK-4830
    8d
    Radiation Recall Pneumonitis with Pneumocystis jirovecii Superinfection and Treatment Induced Hyponatremia in a Patient with Non-Small-Cell Lung Cancer. (PubMed, Diseases)
    We report a unique case of a 65-year-old man with squamous-cell NSCLC and high PD-L1 expression (80%), who developed a rare complication: radiation recall pneumonitis (RRP), with superimposed Pneumocystis jirovecii pneumonia and severe symptomatic hyponatremia induced by trimethoprim/sulfamethoxazole (TMP-SMX). The coexistence of these three complications-radiotherapy- and immunotherapy-associated lung injury, opportunistic infection, and electrolyte imbalance-represents an exceptional clinical scenario not previously described in the literature. This report highlights the importance of differential diagnosis, early recognition of complications, and close monitoring of electrolytes in NSCLC patients undergoing complex treatment regimens.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Keytruda (pembrolizumab)
    10d
    LUCENCE: A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus (clinicaltrials.gov)
    P=N/A, N=212, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | N=350 --> 212
    Trial completion • Enrollment change • Real-world evidence
    |
    Opdivo (nivolumab)
    17d
    Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (clinicaltrials.gov)
    P1/2, N=288, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting | Trial completion date: Oct 2025 --> Jul 2027 | Trial primary completion date: Oct 2025 --> Jul 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule) • EPHA2 (EPH receptor A2)
    |
    Opdivo (nivolumab) • BT5528
    17d
    Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 (clinicaltrials.gov)
    P1/2, N=22, Completed, Laekna Limited | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • PTEN (Phosphatase and tensin homolog) • PI3K (Phosphoinositide 3-kinases)
    |
    ALK rearrangement • EGFR wild-type • KRAS wild-type • RAS wild-type • ALK negative
    |
    docetaxel • Tyvyt (sintilimab) • albumin-bound paclitaxel • afuresertib (LAE002)
    21d
    A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes. (PubMed, Transl Lung Cancer Res)
    In patients receiving first-line paclitaxel/nab-paclitaxel-platinum combined with anti-programmed cell death-1 (PD-1)/PD-L1 antibodies, FGFR2b-positive cohorts exhibited superior outcomes: higher objective response rate (57.4% vs. 41.9%) and prolonged median progression-free survival {11.3 months [95% confidence interval (CI): 6.6-17.9] vs. 6.5 months (95% CI: 5.0-17.3)} compared to FGFR2b-negative counterparts. FGFR2b expression may serve as a predictive biomarker for therapeutic response of FGFR2b-targeted agents in sqNSCLC. The high co-expression rate of FGFR2b and PD-L1 supports the feasibility of combining FGFR2b-targeted agents with immune checkpoint inhibitors as a rational treatment strategy.
    Clinical data • Observational data • Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    PD-L1 expression
    |
    albumin-bound paclitaxel
    23d
    PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance. (PubMed, Ther Adv Med Oncol)
    A genomic expression analysis performed in Cohort #3 (n = 35) showed that a downregulation in the PI3K/AKT/mTOR pathway was mainly evident in the GP group of patients. This integrated multi-step analysis identified potentially altered pathways with a biological impact on squamous-NSCLC oncogenesis, suggesting that the PI3KCA/mTOR pathway could affect the prognosis of resected SCC patients through both genomic aberrations and impaired expression.
    Journal
    |
    SMAD4 (SMAD family member 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDR2 (Discoidin domain receptor 2)
    |
    PIK3CA mutation
    24d
    CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer (clinicaltrials.gov)
    P1/2, N=51, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=242 --> 51 | Trial primary completion date: Dec 2027 --> May 2025
    Enrollment closed • Enrollment change • Trial primary completion date • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK mutation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • CimaVax EGF (EGF-PTI)
    24d
    KEYNOTE-C16: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=145, Completed, Coherus Oncology, Inc. | Active, not recruiting --> Completed | N=260 --> 145 | Trial completion date: Aug 2026 --> Jun 2025 | Trial primary completion date: Dec 2025 --> May 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Loqtorzi (toripalimab-tpzi) • casdozokitug (CHS-388)
    1m
    A Prospective, Multicenter, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Patients with Locally Advanced Squamous Cell Lung Cancer Receiving Concurrent Chemoradiotherapy (ChiCTR2500109840)
    P2, N=32, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    Cosela (trilaciclib)